The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Neogen Corp

Nasdaq: NEOG
Last

(U.S.) $49.33

Today's change-1.74 -3.41%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Neogen Corp

Nasdaq: NEOG
Last

(U.S.) $49.33

Today's change-1.74 -3.41%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Neogen Corp down (U.S.)$1.74

Neogen Corp closed sharply lower Friday, dropping (U.S.)$1.74 or 3.41% to (U.S.)$49.33. Over the last five days, shares have lost 5.46% and are down 12.72% for the last year to date. This security has outperformed the S&P 500 by 10.52% during the last year.

Key company metrics

  • Open(U.S.) $50.88
  • Previous close(U.S.) $51.07
  • High(U.S.) $51.60
  • Low(U.S.) $49.05
  • Bid / Ask-- / --
  • YTD % change-12.72%
  • Volume174,985
  • Average volume (10-day)144,080
  • Average volume (1-month)176,162
  • Average volume (3-month)176,019
  • 52-week range(U.S.) $41.51 to (U.S.) $62.70
  • Beta1.43
  • Trailing P/E52.69×
  • P/E 1 year forward47.69×
  • Forward PEG3.53×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.94
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.70%

Based on its net profit margin of 11.70%, Neogen Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution

Latest Company News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedNov 30, 201511/30/2015Aug 31, 201508/31/2015May 31, 201505/31/2015Feb 28, 201502/28/2015
Revenue80757968
Total other revenue--------
Total revenue80757968
Gross profit38383834
Total cost of revenue41374135
Total operating expense65606456
Selling / general / administrative21202119
Research & development3322
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income15151512
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax14141412
Income after tax9997
Income tax, total5554
Net income9997
Total adjustments to net income--------
Net income before extra. items9997
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9997
Inc. avail. to common incl. extra. items9997
Diluted net income9998
Dilution adjustment------0
Diluted weighted average shares38383838
Diluted EPS excluding extraordinary itemsvalue per share0.240.250.250.20
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.240.250.250.20